171 related articles for article (PubMed ID: 12870005)
21. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels.
Wiegand J; Wedemeyer H; Finger A; Heidrich B; Rosenau J; Michel G; Bock CT; Manns MP; Tillmann HL
Antivir Ther; 2008; 13(4):547-54. PubMed ID: 18672533
[TBL] [Abstract][Full Text] [Related]
22. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
23. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
24. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.
Nafa S; Ahmed S; Tavan D; Pichoud C; Berby F; Stuyver L; Johnson M; Merle P; Abidi H; Trépo C; Zoulim F
Hepatology; 2000 Nov; 32(5):1078-88. PubMed ID: 11050059
[TBL] [Abstract][Full Text] [Related]
25. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy.
Su CW; Wu CY; Hung HH; Wu CH; Sheen IJ; Wu JC
J Gastroenterol Hepatol; 2013 Dec; 28(12):1849-58. PubMed ID: 23730852
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection.
Enomoto M; Nishiguchi S; Tamori A; Kozuka R; Hayashi T; Kohmoto MT; Jomura H; Morikawa H; Murakami Y; Shiomi S; Kawada N
J Interferon Cytokine Res; 2015 Aug; 35(8):613-20. PubMed ID: 25884105
[TBL] [Abstract][Full Text] [Related]
27. Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation.
Zheng SS; Wu J; Liang TB; Wang WL; Huang DS; Xu X
Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):327-9. PubMed ID: 14607701
[TBL] [Abstract][Full Text] [Related]
28. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection.
Yao G; Wang B; Cui Z; Yao J; Zeng M
Chin Med J (Engl); 1999 May; 112(5):387-91. PubMed ID: 11593504
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection.
Shen H; Alsatie M; Eckert G; Chalasani N; Lumeng L; Kwo PY
Clin Gastroenterol Hepatol; 2004 Apr; 2(4):330-6. PubMed ID: 15067628
[TBL] [Abstract][Full Text] [Related]
30. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.
Chen CH; Lu SN; Hung CH; Wang JH; Hu TH; Changchien CS; Lee CM
J Hepatol; 2014 Sep; 61(3):515-22. PubMed ID: 24798617
[TBL] [Abstract][Full Text] [Related]
31. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
León P; Pozo F; Echevarría JM
Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
[TBL] [Abstract][Full Text] [Related]
32. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
[TBL] [Abstract][Full Text] [Related]
33. Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study.
Manns MP; Neuhaus P; Atkinson GF; Griffin KE; Barnass S; Vollmar J; Yeang Y; Young CL;
Transpl Infect Dis; 2001 Mar; 3(1):16-23. PubMed ID: 11429035
[TBL] [Abstract][Full Text] [Related]
34. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.
Perrillo RP; Lai CL; Liaw YF; Dienstag JL; Schiff ER; Schalm SW; Heathcote EJ; Brown NA; Atkins M; Woessner M; Gardner SD
Hepatology; 2002 Jul; 36(1):186-94. PubMed ID: 12085364
[TBL] [Abstract][Full Text] [Related]
35. [Preliminary results of interferon alpha-2a and lamivudine combination therapy regimen in children with chronic hepatitis B].
Aşik Akman S; Cokçeken Okçu S; Anil OH; Köse S; Bakiler AR
Mikrobiyol Bul; 2006; 40(1-2):47-53. PubMed ID: 16775956
[TBL] [Abstract][Full Text] [Related]
36. Viral dynamics in chronic hepatitis B patients treated with lamivudine, lamivudine-famciclovir or lamivudine-ganciclovir.
Wolters LM; Hansen BE; Niesters HG; de Man RA
Eur J Gastroenterol Hepatol; 2002 Sep; 14(9):1007-11. PubMed ID: 12352221
[TBL] [Abstract][Full Text] [Related]
37. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection.
Yuen MF; Wong DK; Yuan HJ; Sum SM; Lai CL
J Clin Microbiol; 2004 Oct; 42(10):4882-4. PubMed ID: 15472371
[TBL] [Abstract][Full Text] [Related]
38. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
de Man RA; Bartholomeusz AI; Niesters HG; Zondervan PE; Locarnini SA
J Hepatol; 1998 Oct; 29(4):669-75. PubMed ID: 9824278
[TBL] [Abstract][Full Text] [Related]
39. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
Tillmann HL; Trautwein C; Bock T; Böker KH; Jäckel E; Glowienka M; Oldhafer K; Bruns I; Gauthier J; Condreay LD; Raab HR; Manns MP
Hepatology; 1999 Jul; 30(1):244-56. PubMed ID: 10385663
[TBL] [Abstract][Full Text] [Related]
40. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]